Dianthus Therapeutics Inc Financials
Dianthus Therapeutics Inc (DNTH) reported $2.0M in revenue for fiscal year 2025, down 67.3% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 10 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Equity-funded research spending, rather than commercial revenue, is the dominant mechanic shaping Dianthus’s reported financial results.
Revenue fell to$2.0M in FY2025 while R&D reached$145.6M , making the company’s operating profile resemble a development program more than a commercial enterprise. Operating cash flow was-$129.1M , smaller than the-$162.3M net loss, indicating that reported losses included noncash or timing effects but still required substantial external funding.
R&D rose from
The balance sheet has a low-debt, equity-heavy posture: debt-to-equity was 0.1x and the current ratio was 13.3x in FY2025. Financing cash inflow reached
Financial Health Signals
Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Dianthus Therapeutics Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Dianthus Therapeutics Inc scores 97.94, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($6.2B) relative to total liabilities ($37.5M). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Dianthus Therapeutics Inc passes 1 of 7 computable financial strength tests (2 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
Dianthus Therapeutics Inc reported a net loss of $162.3M while operations used $129.1M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Dianthus Therapeutics Inc generated $2.0M in revenue in fiscal year 2025. This represents a decrease of 67.3% from the prior year.
Dianthus Therapeutics Inc's EBITDA was -$177.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 74.7% from the prior year.
Dianthus Therapeutics Inc reported -$162.3M in net income in fiscal year 2025. This represents a decrease of 91.1% from the prior year.
Dianthus Therapeutics Inc earned -$4.20 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 64.7% from the prior year.
Cash & Balance Sheet
Dianthus Therapeutics Inc held $51.1M in cash as of fiscal year 2025; long-term debt is not reported for that period.
Dianthus Therapeutics Inc paid $0.00 per share in dividends in fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Dianthus Therapeutics Inc's ROE was -32.9% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 8.8 percentage points from the prior year.
Not reported for fiscal year 2025.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2025: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Capital Allocation
Dianthus Therapeutics Inc invested $145.6M in research and development in fiscal year 2025. This represents an increase of 75.2% from the prior year.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
DNTH Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | $2.0M-67.3% | $6.2M+120.6% | $2.8M-56.0% | $6.4M+334.8% | $1.5M | N/A | $0 | $0 | $0 | $0 |
| R&D Expenses | $175.6M | $145.6M+75.2% | $83.1M+153.1% | $32.8M+11.8% | $29.4M+133.1% | $12.6M-75.1% | $50.6M-14.5% | $59.2M+43.2% | $41.3M+48.2% | $27.9M+382.5% | $5.8M |
| SG&A Expenses | $44.1M | $34.3M+37.4% | $25.0M+37.6% | $18.2M+169.3% | $6.7M+244.7% | $2.0M-93.0% | $28.1M+18.2% | $23.8M+27.6% | $18.6M+137.9% | $7.8M+124.6% | $3.5M |
| Operating Income | -$217.8M | -$177.9M-74.7% | -$101.9M-111.5% | -$48.2M-62.2% | -$29.7M-127.0% | -$13.1M+83.4% | -$78.7M+5.1% | -$83.0M-38.4% | -$60.0M-67.8% | -$35.7M-285.5% | -$9.3M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $163K |
| Income Tax | N/A | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Income | -$192.2M | -$162.3M-91.1% | -$85.0M-95.1% | -$43.5M-52.9% | -$28.5M-117.2% | -$13.1M+82.5% | -$74.9M+2.4% | -$76.8M-33.5% | -$57.5M-62.1% | -$35.5M-276.3% | -$9.4M |
| EPS (Diluted) | — | -$4.20-64.7% | -$2.55 | -$8.45 | -$32.57-117.0% | -$15.01 | -$1.71 | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DNTH Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $530.9M+42.0% | $374.0M+108.5% | $179.4M+115.9% | $83.1M+779.4% | $9.5M-94.2% | $161.6M+0.1% | $161.5M+2.7% | $157.3M+188.8% | $54.5M | N/A |
| Current Assets | $409.4M+45.8% | $280.9M+58.3% | $177.5M+116.3% | $82.0M+773.8% | $9.4M-93.8% | $151.5M+1.1% | $149.8M+3.1% | $145.3M+176.8% | $52.5M | N/A |
| Cash & Equivalents | $51.1M+124.1% | $22.8M-82.8% | $132.3M+761.2% | $15.4M+101.2% | $7.6M-86.9% | $58.2M-10.6% | $65.1M+11.5% | $58.3M+13.5% | $51.4M+1039.0% | $4.5M |
| Accounts Receivable | $52K | $0-100.0% | $294K-93.7% | $4.7M+902.1% | $469K | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $37.5M+74.3% | $21.5M+104.4% | $10.5M-91.7% | $127.5M+377.4% | $26.7M-83.9% | $165.8M+716.0% | $20.3M+74.2% | $11.7M-87.9% | $96.6M | N/A |
| Current Liabilities | $30.7M+66.6% | $18.5M+91.6% | $9.6M+17.1% | $8.2M+53.7% | $5.4M-53.2% | $11.4M-19.0% | $14.1M+35.5% | $10.4M+151.5% | $4.1M | N/A |
| Total Equity | $493.4M+40.0% | $352.5M+108.7% | $168.9M+480.6% | -$44.4M-157.2% | -$17.2M-310.4% | -$4.2M-103.0% | $141.2M-3.1% | $145.6M+445.8% | -$42.1M-374.6% | -$8.9M |
| Retained Earnings | -$336.7M-93.1% | -$174.4M-95.0% | -$89.4M-95.0% | -$45.9M-163.7% | -$17.4M+93.2% | -$254.4M-41.7% | -$179.5M-74.7% | -$102.7M-127.2% | -$45.2M | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill, Long-Term Debt.
DNTH Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$155.4M | -$129.1M-65.1% | -$78.2M-112.1% | -$36.9M-26.8% | -$29.1M-193.5% | -$9.9M+84.5% | -$64.0M-12.1% | -$57.1M-36.3% | -$41.9M-88.1% | -$22.3M-241.0% | -$6.5M |
| Capital Expenditures | N/A | N/A | N/A | N/A | $314K-75.2% | $1.3M+216.0% | $400K-86.9% | $3.1M-60.1% | $7.7M+248.9% | $2.2M+1482.0% | $139K |
| Free Cash Flow | N/A | N/A | N/A | N/A | -$29.4M-163.1% | -$11.2M+82.7% | -$64.4M-7.1% | -$60.2M-21.4% | -$49.6M-102.6% | -$24.5M-266.9% | -$6.7M |
| Investing Cash Flow | -$776.6M | -$122.8M+57.2% | -$286.8M-1516.1% | $20.3M+133.9% | -$59.8M-181169.7% | -$33K+99.7% | -$10.6M-794.2% | $1.5M+101.7% | -$91.7M-4070.2% | -$2.2M-1482.0% | -$139K |
| Financing Cash Flow | $1.0B | $280.1M+9.6% | $255.6M+91.4% | $133.6M+38.2% | $96.7M+548.3% | $14.9M-78.0% | $67.7M+8.7% | $62.3M-56.2% | $142.1M+98.8% | $71.5M+567.4% | $10.7M |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
DNTH Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -8739.3% | -1633.7% | -1704.7% | -462.9% | -886.6% | N/A | N/A | N/A | N/A | N/A |
| Net Margin | -7973.3% | -1362.8% | -1540.9% | -443.8% | -888.1% | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -32.9%-8.8pp | -24.1%+1.7pp | -25.8% | N/A | N/A | N/A | -54.4%-14.9pp | -39.5% | N/A | N/A |
| Return on Assets | -30.6%-7.9pp | -22.7%+1.5pp | -24.3%+10.0pp | -34.3%+104.4pp | -138.7%-92.3pp | -46.4%+1.2pp | -47.5%-11.0pp | -36.6%+28.6pp | -65.2% | N/A |
| Current Ratio | 13.32-1.9x | 15.22-3.2x | 18.43+8.5x | 9.97+8.2x | 1.75-11.5x | 13.26+2.6x | 10.62-3.3x | 13.95+1.3x | 12.68 | N/A |
| Debt-to-Equity | 0.080.0x | 0.060.0x | 0.06 | N/A | N/A | N/A | 0.14+0.1x | 0.08 | N/A | N/A |
| FCF Margin | N/A | N/A | N/A | -457.9% | -756.6% | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Gross Margin.
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Similar Companies
Where Dianthus Therapeutics Inc Ranks
Frequently Asked Questions
What is Dianthus Therapeutics Inc's annual revenue?
Dianthus Therapeutics Inc (DNTH) reported $2.0M in total revenue for fiscal year 2025. This represents a -67.3% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Dianthus Therapeutics Inc's revenue growing?
Dianthus Therapeutics Inc (DNTH) revenue declined by 67.3% year-over-year, from $6.2M to $2.0M in fiscal year 2025.
Is Dianthus Therapeutics Inc profitable?
No, Dianthus Therapeutics Inc (DNTH) reported a net income of -$162.3M in fiscal year 2025.
What is Dianthus Therapeutics Inc's EBITDA?
Dianthus Therapeutics Inc (DNTH) had EBITDA of -$177.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Dianthus Therapeutics Inc's return on equity (ROE)?
Dianthus Therapeutics Inc (DNTH) has a return on equity of -32.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Dianthus Therapeutics Inc's operating cash flow?
Dianthus Therapeutics Inc (DNTH) recorded an outflow of $129.1M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Dianthus Therapeutics Inc's total assets?
Dianthus Therapeutics Inc (DNTH) had $530.9M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Dianthus Therapeutics Inc spend on research and development?
Dianthus Therapeutics Inc (DNTH) invested $145.6M in research and development during fiscal year 2025.
What is Dianthus Therapeutics Inc's current ratio?
Dianthus Therapeutics Inc (DNTH) had a current ratio of 13.32 as of fiscal year 2025, which is generally considered healthy.
What is Dianthus Therapeutics Inc's debt-to-equity ratio?
Dianthus Therapeutics Inc (DNTH) had a debt-to-equity ratio of 0.08 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Dianthus Therapeutics Inc's return on assets (ROA)?
Dianthus Therapeutics Inc (DNTH) had a return on assets of -30.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Dianthus Therapeutics Inc's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Dianthus Therapeutics Inc (DNTH) held $514.4M in cash, cash equivalents and investments, and reported an operating cash outflow of $129.1M over that year. Dividing the one by the other, the reported balance equals about 48 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Dianthus Therapeutics Inc's Altman Z-Score?
Dianthus Therapeutics Inc (DNTH) has an Altman Z-Score of 97.94, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Dianthus Therapeutics Inc's Piotroski F-Score?
Dianthus Therapeutics Inc (DNTH) has a Piotroski F-Score of 1 out of 7 computable signals; 2 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Dianthus Therapeutics Inc's earnings high quality?
Dianthus Therapeutics Inc (DNTH) reported a net loss of $162.3M while operations used $129.1M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Dianthus Therapeutics Inc?
Dianthus Therapeutics Inc (DNTH) scores 52 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.